Send to

Choose Destination
J Clin Endocrinol Metab. 2016 Feb;101(2):599-609. doi: 10.1210/jc.2015-2665. Epub 2015 Nov 18.

Link Between Increased Satiety Gut Hormones and Reduced Food Reward After Gastric Bypass Surgery for Obesity.

Author information

Metabolic and Molecular Imaging Group (A.P.G., A.D.M., S.S., N.C., J.D.B.), Robert Steiner MRI Unit (G.D.), Medical Research Council Clinical Sciences Centre, and Centre for Neuropsychopharmacology (A.P.G.) and Computational, Cognitive, and Clinical Neuroimaging Laboratory (A.P.G., N.C.), Division of Brain Sciences, and Division of Diabetes, Endocrinology, and Metabolism (A.D.M., C.W.l.R.), Imperial College London, Hammersmith Hospital, London W12 0NN, United Kingdom; Diabetes Complications Research Centre (S.J., K.J.N., J.G., S.M., C.W.l.R.), Conway Institute, School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland; Centre National de la Recherche Scientifique Unité Mixte de Recherche 6265 (L.P., S.M.), Centre des Sciences du Goût et de l'Alimentation, and Institut National de la Recherche Agronomique Unité Mixte de Recherche 1324 (L.P., S.M.), Centre des Sciences du Goût et de l'Alimentation, and Unité Mixte de Recherche Centre des Sciences du Goût et de l'Alimentation (L.P., S.M.), Université de Bourgogne, F-21000, Dijon, France; Research Centre for Optimal Health (J.D.B.), University of Westminster, London W1W 6UW, United Kingdom; and Department of Gastro Surgical Research and Education (C.W.l.R.), University of Gothenburg, 41345 Gothenburg, Sweden.



Roux-en-Y gastric bypass (RYGB) surgery is an effective long-term intervention for weight loss maintenance, reducing appetite, and also food reward, via unclear mechanisms.


To investigate the role of elevated satiety gut hormones after RYGB, we examined food hedonic-reward responses after their acute post-prandial suppression.


These were randomized, placebo-controlled, double-blind, crossover experimental medicine studies.


Two groups, more than 5 months after RYGB for obesity (n = 7-11), compared with nonobese controls (n = 10), or patients after gastric banding (BAND) surgery (n = 9) participated in the studies.


Studies were performed after acute administration of the somatostatin analog octreotide or saline. In one study, patients after RYGB, and nonobese controls, performed a behavioral progressive ratio task for chocolate sweets. In another study, patients after RYGB, and controls after BAND surgery, performed a functional magnetic resonance imaging food picture evaluation task.


Octreotide increased both appetitive food reward (breakpoint) in the progressive ratio task (n = 9), and food appeal (n = 9) and reward system blood oxygen level-dependent signal (n = 7) in the functional magnetic resonance imaging task, in the RYGB group, but not in the control groups.


Octreotide suppressed postprandial plasma peptide YY, glucagon-like peptide-1, and fibroblast growth factor-19 after RYGB. The reduction in plasma peptide YY with octreotide positively correlated with the increase in brain reward system blood oxygen level-dependent signal in RYGB/BAND subjects, with a similar trend for glucagon-like peptide-1.


Enhanced satiety gut hormone responses after RYGB may be a causative mechanism by which anatomical alterations of the gut in obesity surgery modify behavioral and brain reward responses to food.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center